TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15801925

Group type: EXPERIMENTAL
Intervention: Micafungin (150 mg/day)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Fluconazole (200 mg/day)
Number of subjects: 523
Study: 12093836

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer
Number of subjects: 515

Group type: COMPARATOR
Intervention: Clinical touch embryo transfer
Number of subjects: 515
Study: 10511329

Group type: EXPERIMENTAL
Intervention: 1800 IU/d of ergocalciferol (vitamin D2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (n=7)
Number of subjects: 18
Study: 7742708

Group type: EXPERIMENTAL
Intervention: 5 atm abs oxygen (HBO)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 atm abs O2 with 190 mmHg inspired PCO2 (hypercapnia)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Air at atmospheric pressure (Control)
Number of subjects: 8
Study: 2127324

Group type: EXPERIMENTAL
Intervention: Clinical pharmacokinetic service
Number of subjects: 75
Study: 7194733

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 32
Study: 30252571

Group type: EXPERIMENTAL
Intervention: One-quarter standard-dose ticagrelor
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Half standard-dose ticagrelor
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standard-dose ticagrelor
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clopidogrel (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ticagrelor groups (all doses)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Half and standard-dose ticagrelor
Number of subjects: 60
Study: 27762434

Group type: EXPERIMENTAL
Intervention: Oxycodone-naloxone
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 62
Study: 25963981

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine-piperaquine (SP-PQ)
Number of subjects: 65
Study: 24411682

Group type: EXPERIMENTAL
Intervention: Continuous, inhibiting TBS (cTBS) to the right dlPFC
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bilateral sham stimulation
Number of subjects: 32
Study: 21104484

Group type: EXPERIMENTAL
Intervention: Self-hypnosis training (HYP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (CR)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined hypnosis-cognitive restructuring intervention (CR-HYP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Education control intervention
Number of subjects: 15
Study: 19202426

Group type: EXPERIMENTAL
Intervention: 20 gauge vitrectomy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 23 gauge vitrectomy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 25 gauge vitrectomy
Number of subjects: 90
Study: 18499625

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 16148323

Group type: EXPERIMENTAL
Intervention: Structured interview (Schedule for Affective Disorders and Schizophrenia for School‐aged Children‐Present and Lifetime Versions) administered by a trained interviewer before the initial physician visit
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Structured interview (Schedule for Affective Disorders and Schizophrenia for School‐aged Children‐Present and Lifetime Versions)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Assessment as usual
Number of subjects: 225
Study: 12133120

Group type: EXPERIMENTAL
Intervention: Nimodipine and dextropropoxiphen (experimental group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dextropropoxiphen and benzodiazepine (control group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Alpha-2-adrenergic agents and naltrexone (control group 2)
Number of subjects: 80
Study: 9918565

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (50 mg DEM hydrobromide orally)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Quinidine (50 mg Qd sulfate orally)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8589013

Group type: EXPERIMENTAL
Intervention: Routine blood tests (alkaline phosphatase, SGOT, gamma-GT, bilirubin, serum calcium, serum creatinine)
Number of subjects: 4105

Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase
Number of subjects: 4105

Group type: EXPERIMENTAL
Intervention: Other routine blood tests (bilirubin, serum calcium, serum creatinine)
Number of subjects: 4105
Study: 2224916

Group type: EXPERIMENTAL
Intervention: Etretinate 25 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 0
Study: 343678

Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (HBIG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immune serum globulin (ISG)
Number of subjects: 0
Study: 31648203

Group type: EXPERIMENTAL
Intervention: Low-intensity stretching
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-intensity stretching
Number of subjects: 14
Study: 31004432

Group type: EXPERIMENTAL
Intervention: Investigational therapeutics for Ebola patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surveillance for Zika and related viruses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Online health assessment survey for U.S. Marines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidrug-Resistant and Virulent Organisms Trauma Infections Initiative
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antimicrobial Resistance and Stewardship Collaborative Clinical Research Consortium
Number of subjects: 0
Study: 28392272

Group type: EXPERIMENTAL
Intervention: Risk score model based on preprocedural risk factors (age, serum creatinine levels, N-terminal pro b-type natriuretic peptide levels, high-sensitivity C-reactive protein, and primary PCI)
Number of subjects: 1777

Group type: EXPERIMENTAL
Intervention: Risk score model developed from the developmental data set (n=1076)
Number of subjects: 1777

Group type: EXPERIMENTAL
Intervention: Risk score model validated in the validation data set (n=701)
Number of subjects: 1777

Group type: EXPERIMENTAL
Intervention: Risk score model (0-36 scale)
Number of subjects: 1777

Group type: EXPERIMENTAL
Intervention: Risk score model
Number of subjects: 1777
Study: 26357943

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy-informed software application (Actissist) plus Treatment As Usual (TAU)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Symptom monitoring software application (ClinTouch) plus Treatment As Usual (TAU)
Number of subjects: 36
Study: 23826104

Group type: EXPERIMENTAL
Intervention: 800 IU ergocalciferol daily until delivery
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Single oral bolus of 200,000 IU cholecalciferol
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Any vitamin D (both supplementation groups combined)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No vitamin D (control group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Atopy (assessed by skin test, serum IgE, exhaled nitric oxide, impulse oscillometry)
Number of subjects: 180
Study: 21419704

Group type: EXPERIMENTAL
Intervention: AAV2‐GAD infusions
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 66
Study: 19641312

Group type: EXPERIMENTAL
Intervention: Triflusal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 30
Study: 17317676

Group type: EXPERIMENTAL
Intervention: Erlotinib treatment
Number of subjects: 25
Study: 15851147

Group type: EXPERIMENTAL
Intervention: MVP
Number of subjects: 30

Group type: COMPARATOR
Intervention: DDD/R
Number of subjects: 30
Study: 11231767

Group type: EXPERIMENTAL
Intervention: Diode laser transscleral cyclophotocoagulation (TSCPC) at 1.5 W for 1.5 seconds
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Diode laser transscleral cyclophotocoagulation (TSCPC) at 1.25 W for 2.5 seconds
Number of subjects: 92
Study: 9771860

Group type: EXPERIMENTAL
Intervention: 6 IU GH twice daily from 2 days before to 7 days after the operation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7819101

Group type: EXPERIMENTAL
Intervention: Interleukin‐10 (IL‐10)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Soluble interleukin‐2 receptor (sIL‐2r)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combination of elevated IL‐10 and sIL‐2r > 3000 U/ml
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combination of IL‐10 with sIL‐2r
Number of subjects: 105
Study: 3046294

Group type: EXPERIMENTAL
Intervention: intravenous anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 240

Group type: COMPARATOR
Intervention: intracoronary streptokinase
Number of subjects: 240
Study: 29746177

Group type: EXPERIMENTAL
Intervention: Narrative advertising
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Role Transportation Theory in advertising
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Role transference
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Truth avoidance
Number of subjects: 305

Group type: COMPARATOR
Intervention: Informative advertising
Number of subjects: 305
Study: 28500373

Group type: EXPERIMENTAL
Intervention: Varenicline (VAR)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 110
Study: 25144403

Group type: EXPERIMENTAL
Intervention: Educational multimedia intervention
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Entertainment video game intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 24206873

Group type: EXPERIMENTAL
Intervention: DCB (3 μg/mm²) followed by CoCr-stent
Number of subjects: 97

Group type: COMPARATOR
Intervention: Stent first followed by DCB
Number of subjects: 97
Study: 20847736

Group type: EXPERIMENTAL
Intervention: PDA with self-monitoring software and daily feedback messages (PDA+FB)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PDA with self-monitoring software
Number of subjects: 210

Group type: COMPARATOR
Intervention: Paper diary/record (PR)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PDA groups
Number of subjects: 210
Study: 18082667

Group type: EXPERIMENTAL
Intervention: 600 mcg of vaginal misoprostol every 6 h up to four doses
Number of subjects: 210

Group type: COMPARATOR
Intervention: 400 mcg of vaginal misoprostol every 4 h up to five doses
Number of subjects: 210
Study: 16678205

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg BID
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD (after switching from placebo)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 87
Study: 12946551

Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1% ophthalmic solution
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 107
Study: 11076429

Group type: EXPERIMENTAL
Intervention: Oral granisetron plus i.v. dexamethasone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intravenous ondansetron plus i.v. dexamethasone
Number of subjects: 51
Study: 9084348

Group type: EXPERIMENTAL
Intervention: Etidronate, 800 mg orally, once per day for 2 weeks of 15 weeks, repeated once.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional treatment (without etidronate).
Number of subjects: 13
Study: 8210923

Group type: EXPERIMENTAL
Intervention: 400 mg etodolac SR once a day for up to 52 weeks
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: 600 mg etodolac SR once a day for up to 52 weeks
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: etodolac SR
Number of subjects: 539
Study: 3730528

Group type: EXPERIMENTAL
Intervention: 50 mg innovator product
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg generic product
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50 mg solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promethazine (all products)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All products
Number of subjects: 0
Study: 31954696

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Biofeedback
Number of subjects: 50
Study: 29757462

Group type: EXPERIMENTAL
Intervention: 200 g guava/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg synthetic vitamin C/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 0
Study: 27424313

Group type: EXPERIMENTAL
Intervention: Combination of n-3 FA 2 g + fenofibrate 160 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of n-3 FA + fenofibrate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 50
Study: 25210025

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6351
Study: 23428122

Group type: EXPERIMENTAL
Intervention: GABA treatment (25-30 mg/kg•d)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional treatment for asthma
Number of subjects: 75
Study: 27534055

Group type: EXPERIMENTAL
Intervention: Affinoleukine (AFL)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no AFL)
Number of subjects: 23
Study: 17971511

Group type: EXPERIMENTAL
Intervention: Pramlintide (30 microg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15772920

Group type: EXPERIMENTAL
Intervention: Intensive medical care delivered by a nurse practitioner and a nephrologist
Number of subjects: 800

Group type: COMPARATOR
Intervention: Care provided by the nephrologist alone
Number of subjects: 800
Study: 12670780

Group type: EXPERIMENTAL
Intervention: montelukast 10mg daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: budesonide 400 microg twice a day (bid)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: montelukast 10 mg daily plus budesonide 400 microg bid
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: budesonide 800 microg bid
Number of subjects: 51
Study: 11910586

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol in 1 g gel daily + 10 mg medroxyprogesterone acetate for the first 12 days every month (Group I)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol in 1 g gel daily + 10 mg medroxyprogesterone acetate for the first 12 days every 3 months (Group II)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol in 1 g gel daily + 10 mg medroxyprogesterone acetate for the first 12 days every month (Group III)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Endometrial safety assessment
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Acceptability of the gel
Number of subjects: 395
Study: 8994285

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt
Number of subjects: 43
Study: 1473437

Group type: EXPERIMENTAL
Intervention: 4 g 5‐ASA foam
Number of subjects: 10

Group type: COMPARATOR
Intervention: 4 g 5‐ASA enema
Number of subjects: 10
Study: 6237836

Group type: EXPERIMENTAL
Intervention: Zimelidine (Z), 200 mg by mouth, preceded by 1 hr and followed for 7 hr of oral ethanol (E) in juice dosed to maintain blood alcohol concentrations between 800 and 1000 mg/l
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo Z and E
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Z and juice
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo Z and juice
Number of subjects: 6

Group type: COMPARATOR
Intervention: E
Number of subjects: 6
Study: 30657249

Group type: EXPERIMENTAL
Intervention: Prehabilitation (exercise counselling session followed by a 13-17 week telephone-guided walking programme)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 78
Study: 28138381

Group type: EXPERIMENTAL
Intervention: d-Cycloserine (DCS) 50 mg administered 30 min prior to group social skills training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo administered 30 min prior to group social skills training
Number of subjects: 60
Study: 27703725

Group type: EXPERIMENTAL
Intervention: Once weekly extended release exenatide for 24 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study: 24326981

Group type: EXPERIMENTAL
Intervention: 300 mg of vitamin E plus 400 mg of vitamin C
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 21890277

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (300 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (never depressed women)
Number of subjects: 28
Study: 19576915

Group type: EXPERIMENTAL
Intervention: High glycemic load (HG) diet
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low glycemic load (LG) diet
Number of subjects: 42
Study: 17727580

Group type: EXPERIMENTAL
Intervention: IV(2) flow medical device
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard gravitational infusion sets without IV(2) flow
Number of subjects: 52
Study: 15077078

Group type: EXPERIMENTAL
Intervention: Amiodarone plus metoprolol
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 15685462

Group type: EXPERIMENTAL
Intervention: Knee joint effusion (experimental condition)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control condition (saline injection)
Number of subjects: 8
Study: 10500939

Group type: EXPERIMENTAL
Intervention: Diazepam premedication group (group D(+), n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No premedication group (group D(-), n = 14)
Number of subjects: 28
Study: 8561329

Group type: EXPERIMENTAL
Intervention: Epinephrine 15 micrograms
Number of subjects: 15

Group type: COMPARATOR
Intervention: Contraction-associated tachycardic responses (CATRs)
Number of subjects: 15
Study: 1895369

Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine (10 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 6282926

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IGIV), 5%, in 10% maltose, administered at a dose of 20 cc/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IGIV), 5%, in 10% maltose, at doses lower than 20 cc/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IGIV) administered at 20 cc/kg once every week (currently under evaluation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IGIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMV immune plasma (for comparison)
Number of subjects: 0
Study: 30666966

Group type: EXPERIMENTAL
Intervention: 2‐L low‐volume bowel preparation regimen
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 4‐L high‐volume bowel preparation regimen
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Resection group (RG) with left colon resection
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Low‐volume preparation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 30247951

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 63

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 63
Study: 27079196

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rTMS-based DTI FT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rTMS combined with rTMS-based DTI FT
Number of subjects: 20

Group type: COMPARATOR
Intervention: DCS
Number of subjects: 20
Study: 25103182

Group type: EXPERIMENTAL
Intervention: AWARE intervention (30-minute patient education)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Routine care only (control group)
Number of subjects: 67
Study: 22130104

Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Tolvaptan 60 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 21153945

Group type: EXPERIMENTAL
Intervention: Nursing-implemented sedation protocol (Group N, n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Daily interruption of sedative infusion (Group P, n=25)
Number of subjects: 50
Study: 18187432

Group type: EXPERIMENTAL
Intervention: Whole bean soy milk
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Soy protein isolate milk
Number of subjects: 28

Group type: COMPARATOR
Intervention: Dairy milk
Number of subjects: 28
Study: 15786484

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy plus family intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 92
Study: 11903077

Group type: EXPERIMENTAL
Intervention: Warming mattress (Group M)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Active i.v. fluid tube warming system (Group T)
Number of subjects: 59
Study: 10443214

Group type: EXPERIMENTAL
Intervention: Self-expandable covered metal Wallstent
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plastic Procter Livingstone tube
Number of subjects: 40
Study: 7797776

Group type: EXPERIMENTAL
Intervention: Insulin-glucose infusion followed by multidose subcutaneous insulin for > or = 3 months
Number of subjects: 620

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 620
Study: 31968396

Group type: EXPERIMENTAL
Intervention: Low-fat diet (n = 40)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 78

Group type: COMPARATOR
Intervention: Moderately high-protein diet (n = 38)
Number of subjects: 78
Study: 31347332

Group type: EXPERIMENTAL
Intervention: MRgFUS thalamotomy with SDR above 0.4
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MRgFUS thalamotomy with SDR above 0.45
Number of subjects: 50

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50
Study: 27930952

Group type: EXPERIMENTAL
Intervention: Food addiction symptoms
Number of subjects: 178
Study: 25847555

Group type: EXPERIMENTAL
Intervention: Tango classes (N=18)
Number of subjects: 40